No Data
We Think Syntara (ASX:SNT) Needs To Drive Business Growth Carefully
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Syntara's Valuation Assumes $750 Million Licensing Deal for Drug Candidate, Eruoz Hartleys Says
Syntara Started at Spec Buy by Euroz Hartleys >SNT.AU
Syntara Develops Drug Candidate for Hypertrophic Scars, Shares Rise 3%
Syntara Ltd: Half Year Report and Appendix 4D
